Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00069758 | Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma | PHASE2 | COMPLETED | 72 | — | — | Sep 1, 2003 | Apr 1, 2007 | May 9, 2014 | 17 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| SDX-105 | DRUG | - |
Inclusion Criteria: * Documented indolent or transformed B-Cell NHL indolent NHL: follicular B-Cell lymphoma, diffuse small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma * Documented refractory disease to rituximab therapy, given as a single agent or in combination (defin...